Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Woman and Man Max 99 years
Sanofi Pasteur MSD
Update Il y a 4 ans
A phase 3 open-label study to evaluate the immune response and the safety of a primary series schedule that includes V419 (PR5I: hexavalent vaccine) at 2 and 6 months of age and Pediacel® (pentavalent vaccine) at 4 months of age Estudio abierto fase III para evaluar la respuesta inmune y la seguridad de un esquema de primovacunación que incluye V419 (PR5I: vacuna hexavalente) a los 2 y 6 meses de edad y Pediacel® (vacuna pentavalente) a los 4 meses de edad
The two co-primary objectives for the study are: -To demonstrate that the mixed schedule induces acceptable responses for Hepatitis B (% of subjects with an anti-HBs titre ≥10 mIU/mL ) one month after...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD SNC
Update Il y a 4 ans
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 2-dose regimen of ProQuad® manufactured with rHA administered to healthy children from 9 months of age
The first primary objective is to demonstrate that a 2-dose regimen of ProQuad® rHA administered at a 3-month interval to healthy childrenof 11 months of age at the time of Dose 1 is as immunogenic ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
A controlled, double-blind and randomized study, to compare the immunogenicity and safety of HEXAVAC manufactured by an upgraded process to HEXAVAC manufactured by the current process when given to healthy infants at 2, 4 & 6 months of age followed by a booster dose at 12 months of age
1. To show, that when HEXAVAC® upgraded process is given in a 3-dose primary series at 2, 4 and 6 months of age, followed by a booster dose at 12 months the anti-HBs seroprotection rate one month post...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
A 24-week, multicenter, international, randomized (1:1), parallel-group, open-label, comparative study of insulin glargine versus liraglutide in insulin-naïve patients with Type 2 diabetes treated with oral agents and not adequately controlled, followed by a 24-week extension period with insulin glargine for patients not adequately controlled with liraglutide
The primary objective of this study is to demonstrate the superiority of insulin glargine over liraglutide in terms of percentage of patients reaching a HbA1c < 7% at the end of the comparative period...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Max and 21 years
Sanofi
Update Il y a 4 ans
Sanofi-Aventis EFC10339 : Essai de phase 2 randomisé évaluant un traitement d’induction associant docétaxel à une chimiothérapie par cisplatine, 5-fluorouracil chez des patients jeunes ayant un carcinome nasopharyngé. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyngeal...
Country
France
organs
Pharynx
Specialty
Chimiothérapie
,
Pédiatrie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi Pasteur Inc
Update Il y a 4 ans
Comparison of Pertussis Specific Cellular and Humoral Immunity Before and After a Acellular Pertussis Booster-Vaccineation in Combination With a Diphtheria-Tetanus-Polio-Vaccine Between Three Groups of Adolescents 10-14 Years of Age That Have Previously Either Received 4 or 5 Doses of Acellular Pertussis Vaccine or 4 Doses of of Whole-Cell Pertussis Vaccine
Evaluation of the pertussis-specific humoral and cellular immunity after vaccination with REPEVAX® or COVAXiS® or COVAXiS® + IPV Merieux® among three groups: Group A: Adolescents 10-14 years of age w...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
SOLTI NEOPARP : Essai de phase 2 randomisé évaluant l’efficacité et la tolérance de différents schémas d’administration du paclitaxel associé ou non à de l’iniparib (BSI-201), chez des patientes ayant un cancer du sein triple négatif. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance de différents schémas d’administration du paclitaxel associé ou non à de l’iniparib (BSI-201), chez des patientes ayant un cancer du ...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
Sanofi-Aventis EFC10203 : Essai de phase 3 randomisé comparant l’efficacité et la tolérance d’un traitement par S-1 à du 5-FU chez des patients ayant un cancer du pancréas. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A multicenter, open-label, randomized study comparing efficacy and safety of S-1 as single agent versus 5-FU bolus for the treatment of patients with metastatic pancreatic cancer previously treated wi...
Country
France
organs
Pancréas
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve patients with type 2 diabetes
The first primary objective is to assess the antidiabetic effect of rimonabant (HbA1C) over a period of 6 months when prescribed in treatment-naïve type 2 diabetes patients.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi Pasteur
Update Il y a 4 ans
Safety and Immunogenicity of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Adult and Elderly Subjects
To demonstrate non-inferiority of antibody responses induced by QIV compared with the licensed 2011-2012 TIV (containing the B/Brisbane strain) and the investigational TIV (containing the B/Florida st...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
10
11
12
13
14
15
16
17
18
19
Next